The FDA expanded the indication for insulin aspart injection 100 U/mL to include use in insulin infusion pumps for the improvement of glycemic response in adults with type 1 and type 2 diabetes, according to a press release from Novo Nordisk.
The FDA approved insulin aspart (Fiasp), a rapid-acting injection, in 2017 for use by IV infusion under supervision by a health care professional or by subcutaneous multiple daily injection (MDI) in adults with diabetes. The insulin aspart injection was a new formulation of NovoLog that includes niacinamide, which helps increase the speed of insulin
Anupam Ghose, a physician by training, was diagnosed with Type 2 Diabetes Mellitus (T2DM) in 2017. After the diagnosis of T2DM, he followed a low carbohydrate high fat diet and reversed his T2DM within a year. Now he has one main goal in life and that is to make people understand that the conventional method of treating T2DM is not beneficial. Type 2 diabetes is reversible and the best way to reverse T2DM is through diet and lifestyle modifications. He now decided to help people with type 2 diabetes by offering online coaching to reverse their diabetes.